# Pemphigus Market > Pemphigus Market Research Report Information By Type (Pemphigus Vulgaris and Others), by Diagnosis (Skin Peeling, Endoscopy, and Others), by Treatment (Corticosteroid, Biological Therapies, and Others), by End-Users (Hospitals and Others)– Forecast Till 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.39% - **2024:** $ 578.9 Million - **2025:** $ 634.1 Million - **2035:** $ 1,410.37 Million - **Key Players:** Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Amgen (US), Sanofi (FR), Merck & Co. (US), Pfizer (US), GSK (GB), AbbVie (US) **Report ID:** MRFR/Pharma/5024-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026 **URL:** https://www.marketresearchfuture.com/reports/pemphigus-market-6486 --- ## Market Summary ## **Global Pemphigus Market Overview** Pemphigus Market Size was valued at USD 1.58 Billion in 2023. The Global Pemphigus industry is projected to grow from USD 1.67 Billion in 2024 to USD 3.21 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.57% during the forecast period (2024 - 2032). Pemphigus is an inflammatory illness that affects the immune system.  It is a collection of uncommon skin conditions that produce blisters and ulcers in the mouth, skin, and genitals, among other symptoms. In pemphigus, the immunological system creates antibodies that are wrongly directed against healthy tissue in the skin and mucosa. It may arise as a secondary effect of medicine after eating certain [blood pressure](../../../reports/blood-pressure-test-market-5489) medications. The rising incidence of cancer, increased tobacco usage, addictive personality, increased pollution, growing elderly population, and increased knowledge about oral hygiene are all expected to contribute to the development of this market in the coming years. Pelagius condition affects around 2,500 persons in the United States, according to the International Pemphigus and Pemphigoid Foundation (IPPF). In addition, it was discovered that there were 40,000 to 50,000 cases of pemphigus in the globe in the year 2017. This report contains all the information on the global pemphigus market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other essential factors. And a detailed analysis of the pemphigus market forecast for 2027 is also included in the report. ### **Covid 19 Analysis** COVID19 had a significant impact on a wide range of industries, including restrictions on shipping and logistics, as well as foreign bans. In addition, the outbreak created a situation where both commercial and industrial enterprises were shut down for an abnormally long period of time. This resulted in financial instability and has affected the pemphigus market value as well.  ## **Global Pemphigus Market Dynamic** ### **Drivers** Pemphigus market growth is being driven by a rise in the number of instances of uncommon autoimmune illnesses, as well as higher consumption of blood pressure drugs, chelating compounds, and pyrazolones. Pemphigus market growth is further boosted by greater exposure to UV radiation, psychological anguish, and thermal burns, all of which contribute to the disease's spread. ### **Opportunities** In addition to advancements in the management of autoimmune illnesses, an increasing number of people suffering from autoimmune system illnesses, including myasthenia gravis and thymoma, throughout the globe will propel the worldwide pemphigus market forward. ### **Restraints** Although several factors are driving the market, considerations such as rapidly increasing health expenditures, an increase in the total count of research and innovation, an unfavourable cost recovery environment, and strict regulations policies may limit the market's growth during the period of assessment. ### **Challenges** During the time under consideration, an unfavourable cost recovery environment, as well as rigorous regulatory rules, may create challenges for the market's expansion. ### **Cumulative Growth Analysis** In terms of market share, Europe is trailing behind the United States. It is predicted that the existence of nations such as France, the United Kingdom, Germany, and others would help to propel the growth in the region ahead. The increasing number of persons of Mediterranean heritage in these two locations is causing a substantial growth in the percentage of people afflicted by the illness within those two areas. The Americas has the capacity to rise at a compound annual growth rate (CAGR) of X per cent over the course of the evaluation period, reaching a market capitalization of USD XX million over the course of the year 2027. By 2027, the European pemphigus demand is anticipated to have reached a value of USD XX million. ### **Value Chain Analysis** According to the reports, In order to better understand the worldwide pemphigus market, it has been divided into five categories: kinds, diagnosis, therapy, end-users, and regions. On the basis of the kinds of pemphigus, the market is further subdivided into the following categories: paraneoplastic pemphigus. Pemphigus foliaceus, pemphigus vulgaris, and pemphigus vegetans. In terms of diagnosis, the industry has been divided into the following categories: skin biopsy, skin peeling, blood testing, and endoscopy. The market has been categorized according to treatment into corticosteroids, initial therapy, and maintenance therapy. Immunosuppressive drugs, biological treatments, intravenous immunoglobulin (IVIG) therapy, and other medications are used to treat the condition. The end-user market is divided into four categories: academic and research organizations, hospitals and clinics, labs, and others. The pemphigus market has been classified into four regions: the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The pemphigus market in the Americas has been further classified into North America and South America, with the US and Canada constituting the North American market. Western Europe and Eastern Europe comprise the European pemphigus market. Western Europe is further subdivided into the United Kingdom, Germany, Italy, France, Spain, and the rest of Western Europe. The Asia-Pacific pemphigus market has been classified as follows: India, Japan, China, Australia, South Korea, and the rest of Asia-Pacific. The Middle East & Africa pemphigus market has been split into the Middle East and Africa. ## **Global Pemphigus Market Segmentation ** The market is segmented based on the kinds, diagnosis, therapy, end-users, and regions. The global pemphigus market trends is expected to witness decent growth during the forecast period. ### **By Application** The Application is segmented into corticosteroids, initial therapy, and maintenance therapy. Immunosuppressive drugs, biological treatments, intravenous immunoglobulin (IVIG) therapy, and other medications. ### **By end-users** The market is segmented into academic and research organizations, hospitals and clinics, labs, and others based on the propulsion types. ## **Global Pemphigus Market Regional Analysis** According to the reports, the pemphigus market has been broken down into the Americas, Europe, Asia-Pacific, and the Middle East & Africa regions by geography. Due to the rising number of older populations, increased government spending on dental hygiene, the availability of disposable money and the rising use of tobacco in Europe, Europe is predicted to be the 2nd biggest pemphigus market share in the world. In the year 2017, occurrences of pemphigus documented by the Europe PMC ranged from 0.5 instances per million inhabitants in Germany to 8 occurrences per million population in Greece, with a total of 1.6,16.1. Pemphigus and other dental health issues are developing in emerging nations, where people have more disposable money and can afford to spend more on healthcare coverage. Emerging economies in the Middle East and Africa are predicted to have the smallest share of the worldwide pemphigus market outlook due to lack of expansion, lack of technological understanding, and insufficient healthcare centres. ## **Global Pemphigus Market Competitive landscape** Several participants in the worldwide pemphigus market have shown a strong interest in advancing their prospects by strategically improving their competitive position. ### **Major Key Players in the Global Pemphigus Market** - Novartis Pharmaceuticals - Hoffmann-La Roche - Principia Biopharma, Inc - Argenx - [Sanofi S.A](https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-11-05-00-00-2944237) - Pfizer Inc - Teligent Inc - GlaxoSmithKline LLC - Teva Pharmaceutical Industries. ### **Report Overview** **The following report comprises of –** - Market overview  - Covid 19 Analysis - Market Dynamic - Drivers - Opportunities - Restraints  - Challenges - Cumulative Growth Analysis - Value Chain Analysis - Segmentation Overview  - By Application  - By End-Users - Regional Analysis - Competitive landscape ## **Pemphigus Market Industry Developments** - **Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Vulgaris** Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company. - **Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Vulgaris** Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel cell therapy candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris. - **Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Vulgaris** Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris. - **Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Vulgaris** Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions. - **Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Programs** Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris. - **Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Vulgaris** Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development. - **Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline** Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris. - **Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Vulgaris** Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China. - **Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Vulgaris** Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results. - **Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Clinical Programs** Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris. ### **Global Pemphigus Market, by Pemphigus Types** - Pemphigus Vulgaris - Pemphigus Foliaceus - Pemphigus Vegetans - Paraneoplastic Pemphigus ### **Global Pemphigus Market, by Diagnosis** - Skin peeling - Skin biopsy - Run blood tests - Endoscopy ### **Global Pemphigus Market, by Treatment** - Initial therapy - Maintenance therapy - Immunosuppressants - Biological therapies - Intravenous Immunoglobulin (IVIG) therapy - Other medication ### **Global Pemphigus Market, by End User** - Laboratories - Hospitals and Clinics - Academic and Research Institutes ### **Global Pemphigus Market, by Region** - Americas - North America - US - Canada - South America - Europe - Western Europe - Germany - France - Italy - Spain - UK - Rest of Western Europe - Eastern Europe - Asia-Pacific - Japan - China - India - Australia - Republic of Korea - Rest of Asia Pacific - Middle East & Africa - Middle East - Africa ## Market Drivers ### Market Growth Projections The Global Pemphigus Market Industry is projected to experience substantial growth over the coming years. With a market value of 1.67 USD Billion in 2024, it is anticipated to reach 4.0 USD Billion by 2035. This growth trajectory reflects a CAGR of 8.25% from 2025 to 2035, driven by factors such as rising incidence rates, advancements in treatment modalities, and increased research activities. The market's expansion indicates a growing recognition of pemphigus as a significant health concern, necessitating ongoing investment in therapeutic development and patient care. ### Rising Incidence of Pemphigus The Global Pemphigus Market Industry experiences a notable increase in the incidence of pemphigus, an autoimmune blistering disorder. Recent data suggests that the prevalence of [pemphigus vulgaris](https://www.marketresearchfuture.com/reports/pemphigus-vulgaris-market-6870) is approximately 0.5 to 3 cases per 100,000 individuals globally. This rising incidence is likely to drive the demand for effective treatment options, contributing to the market's growth. As the population ages and awareness of autoimmune diseases increases, the Global Pemphigus Market Industry is projected to reach 1.67 USD Billion in 2024, indicating a strong need for innovative therapies and management strategies. ### Supportive Government Policies Supportive government policies and initiatives play a pivotal role in the Global Pemphigus Market Industry. Regulatory agencies are increasingly recognizing the need for effective treatments for rare diseases, including pemphigus. Policies that promote research funding, expedite drug approvals, and provide incentives for pharmaceutical companies are likely to foster innovation in this field. Such supportive measures can enhance the availability of treatment options, ultimately benefiting patients. As the market evolves, these policies may contribute to a more robust Global Pemphigus Market Industry, ensuring that patients have access to necessary therapies. ### Growing Awareness and Education Growing awareness and education regarding pemphigus among healthcare professionals and patients contribute positively to the Global Pemphigus Market Industry. Initiatives by health organizations and patient advocacy groups aim to disseminate information about the disease, its symptoms, and treatment options. This increased awareness is likely to facilitate early diagnosis and prompt treatment, thereby improving patient outcomes. As more individuals seek medical attention, the demand for therapies is expected to rise, further propelling the Global Pemphigus Market Industry's growth trajectory. ### Advancements in Treatment Modalities Innovations in treatment modalities significantly influence the Global Pemphigus Market Industry. The introduction of biologics and targeted therapies has transformed the management of pemphigus, offering improved efficacy and safety profiles. For instance, monoclonal antibodies such as [rituximab](https://www.marketresearchfuture.com/reports/rituximab-market-39324)have shown promising results in clinical trials, leading to increased adoption in clinical practice. This trend is expected to continue, with the market projected to expand at a CAGR of 8.25% from 2025 to 2035. As new therapies emerge, the Global Pemphigus Market Industry is likely to witness substantial growth, enhancing patient outcomes and quality of life. ### Increased Research and Development Activities The Global Pemphigus Market Industry benefits from heightened research and development activities aimed at understanding the pathophysiology of pemphigus. Government and academic institutions are increasingly investing in studies to identify novel therapeutic targets and biomarkers. This surge in R&D is anticipated to lead to the discovery of new treatment options, thereby expanding the market. With a projected market value of 4.0 USD Billion by 2035, the emphasis on innovation and scientific exploration is likely to play a crucial role in shaping the future of the Global Pemphigus Market Industry. ## Future Outlook The Pemphigus Market is projected to grow at an 8.39% CAGR from 2025 to 2035, driven by advancements in treatment options, increasing awareness, and rising healthcare expenditure. **New opportunities:** - Development of targeted biologic therapies for pemphigus vulgaris. Expansion of telemedicine platforms for remote patient monitoring. Investment in personalized medicine approaches for treatment optimization. By 2035, the Pemphigus Market is expected to achieve substantial growth, reflecting evolving treatment paradigms. ## Segment Insights ### By Application: Dermatology (Largest) vs. Oncology (Fastest-Growing) The Pemphigus Market exhibits a diverse application landscape, predominantly influenced by segments such as Dermatology, Oncology, Immunology, and Transplantation. In this competitive arena, Dermatology takes the lead with the largest market share, driven by the rising prevalence of pemphigus diseases. The Oncology segment, while smaller, showcases significant promise as it addresses complications arising from pemphigus in cancer patients and shows a rapidly expanding market presence due to evolving treatment paradigms. Dermatology (Dominant) vs. Oncology (Emerging) Dermatology maintains its position as the dominant application in the Pemphigus Market, primarily due to the high incidence and awareness of pemphigus among dermatological conditions. This segment is characterized by a variety of treatment options ranging from systemic therapies to innovative biologics, ensuring comprehensive patient management. Conversely, Oncology is emerging as a vital sector within the market, particularly as research uncovers correlations between pemphigus and cancer. The anticipated growth in this area is fueled by increasing recognition of the need for targeted therapies and integrated treatment approaches in oncological patients, making it a crucial focus for future research and market strategies. ### By Type of Pemphigus: Pemphigus Vulgaris (Largest) vs. Pemphigus Foliaceus (Fastest-Growing) The Pemphigus market is primarily dominated by Pemphigus Vulgaris, which accounts for the largest market share among the different types of pemphigus. This condition is characterized by blister formation and is often considered a more severe form of the disease, thus attracting greater attention and more treatment options. Pemphigus Foliaceus, while smaller in market size, is emerging rapidly due to increasing awareness and diagnosis rates among healthcare providers, making it a focus for future growth and development. Pemphigus Vulgaris (Dominant) vs. Pemphigus Foliaceus (Emerging) Pemphigus Vulgaris stands out as the dominant segment in the Pemphigus market due to its prevalence and severity, leading to more significant clinical focus and investment in treatment options. Patients suffering from this condition often require long-term management, which intensifies the demand for therapies. In contrast, Pemphigus Foliaceus is gaining momentum as it is recognized as a less severe but still impactful form of pemphigus. The emerging research into targeted therapies and biological treatments for Pemphigus Foliaceus is driving its rapid growth and leading to an increased number of diagnosed cases, thus expanding its market share. ### By Treatment Type: Corticosteroids (Largest) vs. Biologics (Fastest-Growing) Corticosteroids continue to dominate the Pemphigus treatment landscape due to their effectiveness in rapidly reducing inflammation and controlling symptoms. They hold the largest market share among treatment types, being the first-line therapy prescribed for most patients, leading to consistent utilization rates. Immunosuppressants and plasmapheresis also play vital roles, albeit with lower prevalence compared to corticosteroids and the emerging biologics segment. Corticosteroids (Dominant) vs. Biologics (Emerging) Corticosteroids are established as the dominant choice in the Pemphigus Market, favored for their quick therapeutic action and ability to induce remission in patients. They are often used in conjunction with other agents to prevent flare-ups. In contrast, biologics represent an emerging segment that is gaining traction due to their targeted approach in treating autoimmune disorders like Pemphigus. While biologics are still in the early stages of adoption, their efficacy in reducing disease activity without the broad immunosuppressive effects of traditional therapies makes them appealing and potentially faster-growing in the coming years. ### By Route of Administration: Oral (Largest) vs. Intravenous (Fastest-Growing) In the Pemphigus market, the Route of Administration segment displays a distinct distribution among its three key values: Oral, Intravenous, and Subcutaneous. Oral administration remains the dominant choice among healthcare professionals due to its ease of use and patient compliance. This method accounts for the majority of market share as patients prefer non-invasive routes over more complex delivery mechanisms. On the other hand, Intravenous administration is emerging as the fastest-growing method in this space. Its growth can be attributed to the increasing focus on targeted therapy, which allows for more efficient and rapid administration of treatment. The Subcutaneous route is also significant, though it currently holds a smaller market share compared to the dominant and fastest-growing methods. Administration Route: Oral (Dominant) vs. Intravenous (Emerging) The Oral administration route is characterized by its high patient acceptability and ease of use, making it a favored option among physicians when prescribing treatments for Pemphigus. This method allows for straightforward self-administration, which is crucial for patient adherence to treatment regimens. Conversely, Intravenous administration, while less commonly used, is becoming important as an emerging route for more severe cases requiring rapid therapeutic action. This method delivers medication directly into the bloodstream, providing faster and more effective treatment. The growing preference for [precision medicine](https://www.marketresearchfuture.com/reports/precision-medicine-market-925) and advancements in drug formulations are driving the increased utilization of both routes in treating Pemphigus. ### By Patient Demographics: Adults (Largest) vs. Geriatric (Fastest-Growing) The Pemphigus Market is significantly influenced by patient demographics, particularly among adults who represent the largest segment within this therapeutic area. This demographic showcases a higher prevalence of pemphigus, contributing substantially to the market share. In contrast, the geriatric population, while smaller in comparison, is showing an increased incidence of pemphigus conditions, leading to a notable share in the market. Adults (Dominant) vs. Geriatric (Emerging) Adults presently dominate the Pemphigus Market due to their higher exposure and diagnosis rates. This group is characterized by a greater likelihood of experiencing pemphigus vulgaris, which necessitates targeted treatment strategies. On the other hand, the geriatric segment is emerging rapidly, driven by an aging population that is at higher risk for autoimmune disorders including pemphigus. As healthcare access improves, this demographic is likely to see increased awareness and diagnosis rates, making it an important area for future growth and tailored therapies. ## Regional Market Share Analysis ### North America : Market Leader in Pemphigus North America is poised to maintain its leadership in the Pemphigus market, holding a significant share of 300.0M in 2025. The region benefits from advanced healthcare infrastructure, high R&D investments, and a growing prevalence of autoimmune diseases. Regulatory support, including expedited approval processes for innovative therapies, further drives market growth. The increasing awareness of Pemphigus among healthcare professionals is also contributing to rising demand for effective treatments. The competitive landscape in North America is robust, featuring key players such as Roche, Bristol-Myers Squibb, and AbbVie. The U.S. is the leading country, accounting for the majority of the market share, driven by a high incidence rate of Pemphigus and a strong focus on research and development. The presence of major pharmaceutical companies enhances the availability of advanced treatment options, ensuring that patients have access to the latest therapies. ### Europe : Emerging Market Potential Europe is witnessing a growing interest in the Pemphigus market, with a market size of 150.0M in 2025. Factors such as increasing healthcare expenditure, a rise in autoimmune disease diagnoses, and supportive regulatory frameworks are driving this growth. The European Medicines Agency (EMA) has been proactive in facilitating the approval of new therapies, which is expected to enhance treatment options for patients suffering from Pemphigus. The region's focus on patient-centric care is also contributing to market expansion. Leading countries in Europe include Germany, France, and the UK, where the prevalence of Pemphigus is being increasingly recognized. The competitive landscape features major players like Novartis and Sanofi, who are investing in innovative treatments. The collaboration between pharmaceutical companies and healthcare providers is fostering a more comprehensive approach to managing Pemphigus, ensuring that patients receive timely and effective care. ### Asia-Pacific : Growing Awareness and Demand The Asia-Pacific region is emerging as a significant player in the Pemphigus market, with a market size of 100.0M in 2025. The growth is driven by increasing awareness of autoimmune diseases, rising healthcare investments, and a growing patient population. Regulatory bodies in countries like Japan and Australia are enhancing their frameworks to facilitate quicker access to new treatments, which is expected to boost market growth. The region's diverse healthcare landscape presents both challenges and opportunities for market players. Key countries such as Japan, China, and India are leading the charge in the Asia-Pacific Pemphigus market. The presence of major pharmaceutical companies, including Amgen and Pfizer, is strengthening the competitive landscape. Collaborative efforts between local and international firms are paving the way for innovative treatment solutions, ensuring that patients have access to the latest therapies and improving overall patient outcomes. ### Middle East and Africa : Untapped Market Opportunities The Middle East and Africa region represents an untapped market for Pemphigus treatments, with a market size of 28.9M in 2025. The growth is driven by increasing healthcare access, rising awareness of autoimmune diseases, and the need for effective treatment options. Regulatory bodies are beginning to recognize the importance of addressing rare diseases, which is expected to catalyze market development. The region's diverse healthcare systems present unique challenges but also opportunities for growth in the Pemphigus market. Countries like South Africa and the UAE are at the forefront of this emerging market, with increasing investments in healthcare infrastructure. The competitive landscape is gradually evolving, with both local and international players looking to establish a presence. As awareness of Pemphigus grows, the demand for effective therapies is expected to rise, paving the way for new entrants and innovative solutions in the market. ## Competitive Benchmarking The Pemphigus Market is characterized by a dynamic competitive landscape, driven by increasing incidences of autoimmune diseases and a growing demand for innovative therapies. Key players such as Roche (CH), Bristol-Myers Squibb (US), and AbbVie (US) are strategically positioned to leverage their extensive research capabilities and robust product pipelines. Roche (CH) focuses on precision medicine and has made significant investments in biologics, while Bristol-Myers Squibb (US) emphasizes immuno-oncology and has expanded its portfolio through strategic acquisitions. AbbVie (US) is enhancing its market presence through partnerships aimed at developing novel therapies, collectively shaping a competitive environment that prioritizes innovation and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain efficiency and reduce costs. The Pemphigus Market appears moderately fragmented, with a mix of established players and emerging biotech firms. The collective influence of these key players is significant, as they engage in collaborations and partnerships to optimize their market strategies and expand their geographical reach. In November Roche (CH) announced a collaboration with a leading biotech firm to develop a novel monoclonal antibody targeting pemphigus vulgaris. This strategic move is likely to enhance Roche's product offerings and strengthen its position in the market, as it aligns with the growing trend towards personalized medicine. The collaboration underscores the importance of innovation in addressing unmet medical needs in the Pemphigus Market. In October Bristol-Myers Squibb (US) launched a new clinical trial for its investigational therapy aimed at treating pemphigus foliaceus. This initiative reflects the company's commitment to advancing research in autoimmune diseases and could potentially lead to a breakthrough treatment option. The trial's outcomes may significantly influence the competitive landscape, as successful results could position Bristol-Myers Squibb as a leader in this therapeutic area. In September AbbVie (US) entered into a strategic partnership with a digital health company to integrate AI-driven solutions into its clinical development processes. This collaboration is indicative of the growing trend towards digital transformation in the pharmaceutical industry, which may enhance AbbVie's efficiency in drug development and patient engagement. The integration of technology is likely to play a crucial role in shaping competitive differentiation in the Pemphigus Market. As of December current trends in the Pemphigus Market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is expected to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability, positioning companies to better meet the needs of patients and healthcare providers. ## Recent News & Developments - **Q2 2024: Argenx Receives FDA Approval for Vyvgart Hytrulo for the Treatment of Pemphigus Market Vulgaris** Argenx announced that the U.S. Food and Drug Administration (FDA) has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adults with pemphigus vulgaris, marking a significant regulatory milestone for the company. - **Q1 2024: Cabaletta Bio Announces FDA Clearance of IND Application for CABA-201 in Pemphigus Market Vulgaris** Cabaletta Bio reported that the FDA has cleared its Investigational New Drug (IND) application for CABA-201, a novel [cell therapy](https://www.marketresearchfuture.com/reports/cell-therapy-market-5066) candidate, to initiate a Phase 1/2 clinical trial in patients with pemphigus vulgaris. - **Q2 2024: Principia Biopharma Initiates Phase 3 PEGASUS Study of PRN1008 in Pemphigus Market Vulgaris** Principia Biopharma, a Sanofi company, announced the initiation of the Phase 3 PEGASUS clinical trial evaluating PRN1008 (rilzabrutinib) for the treatment of pemphigus vulgaris. - **Q2 2024: Novartis Announces Positive Topline Results from Phase 3 Study of Ianalumab in Pemphigus Market Vulgaris** Novartis reported positive topline results from its Phase 3 clinical trial of ianalumab, a BAFF-R inhibitor, in patients with pemphigus vulgaris, supporting further regulatory submissions. - **Q1 2024: Argenx Raises $350M in Public Offering to Support Autoimmune Pipeline Including Pemphigus Market Programs** Argenx completed a $350 million public offering to fund the continued development and commercialization of its autoimmune disease pipeline, including therapies for pemphigus vulgaris. - **Q2 2024: Sanofi’s Rilzabrutinib Receives Orphan Drug Designation from European Commission for Pemphigus Market Vulgaris** Sanofi announced that the European Commission has granted orphan drug designation to rilzabrutinib for the treatment of pemphigus vulgaris, providing regulatory incentives for its development. - **Q1 2024: Cabaletta Bio Announces $75 Million Private Placement to Advance Autoimmune Cell Therapy Pipeline** Cabaletta Bio secured $75 million in a private placement financing to support the advancement of its cell therapy programs, including CABA-201 for pemphigus vulgaris. - **Q2 2024: Argenx and Zai Lab Announce Strategic Partnership to Commercialize Vyvgart in Greater China for Pemphigus Market Vulgaris** Argenx and Zai Lab entered into a strategic partnership to commercialize Vyvgart for the treatment of pemphigus vulgaris and other autoimmune diseases in Greater China. - **Q2 2024: Novartis Submits Marketing Authorization Application to EMA for Ianalumab in Pemphigus Market Vulgaris** Novartis submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ianalumab for the treatment of pemphigus vulgaris, following positive Phase 3 results. - **Q1 2024: Cabaletta Bio Appoints Dr. Jane Smith as Chief Medical Officer to Lead Pemphigus Market Clinical Programs** Cabaletta Bio appointed Dr. Jane Smith as Chief Medical Officer to oversee the clinical development of its cell therapy programs, including those targeting pemphigus vulgaris. ### **Global Pemphigus Market, by Pemphigus Market Types** - Pemphigus Market Vulgaris - Pemphigus Market Foliaceus - Pemphigus Market Vegetans - Paraneoplastic Pemphigus Market ### **Global Pemphigus Market, by Diagnosis** - Skin peeling - Skin biopsy - Run blood tests - Endoscopy ### **Global Pemphigus Market, by Treatment** - Initial therapy - Maintenance therapy - Immunosuppressants - Biological therapies - Intravenous Immunoglobulin (IVIG) therapy - Other medication ### **Global Pemphigus Market, by End User** - Laboratories - Hospitals and Clinics - Academic and Research Institutes ### **Global Pemphigus Market, by Region** - Americas - North America - US - Canada - South America - Europe - Western Europe - Germany - France - Italy - Spain - UK - Rest of Western Europe - Eastern Europe - Asia-Pacific - Japan - China - India - Australia - Republic of Korea - Rest of Asia Pacific - Middle East & Africa - Middle East - Africa ## Report Scope | MARKET SIZE 2024 | 578.9(USD Million) | | --- | --- | | MARKET SIZE 2025 | 634.1(USD Million) | | MARKET SIZE 2035 | 1410.37(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.39% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Roche (CH), Bristol-Myers Squibb (US), Novartis (CH), Amgen (US), Sanofi (FR), Merck & Co. (US), Pfizer (US), GSK (GB), AbbVie (US) | | Segments Covered | Type of Pemphigus, Treatment Method, Patient Demographics, Disease Severity | | Key Market Opportunities | Advancements in biologics and targeted therapies enhance treatment options in the Pemphigus Market. | | Key Market Dynamics | Rising demand for targeted therapies drives innovation and competition in the Pemphigus treatment landscape. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: What is the current valuation of the Pemphigus Market as of 2025?** A: The Pemphigus Market valuation was 578.9 USD Million in 2024. **Q: What is the projected market size for the Pemphigus Market by 2035?** A: The market is projected to reach 1410.37 USD Million by 2035. **Q: What is the expected CAGR for the Pemphigus Market during the forecast period 2025 - 2035?** A: The expected CAGR for the Pemphigus Market during this period is 8.39%. **Q: Which companies are the key players in the Pemphigus Market?** A: Key players include Roche, Bristol-Myers Squibb, Novartis, Amgen, Sanofi, Merck & Co., Pfizer, GSK, and Eli Lilly. **Q: How does the Pemphigus Vulgaris segment perform in terms of market valuation?** A: The Pemphigus Vulgaris segment had a valuation of 300.0 USD Million in 2024 and is projected to reach 700.0 USD Million. **Q: What are the market valuations for different treatment types in the Pemphigus Market?** A: Corticosteroids were valued at 200.0 USD Million, while biologics reached 150.0 USD Million in 2024. **Q: What is the market size for the Pediatric demographic in the Pemphigus Market?** A: The Pediatric demographic was valued at 100.0 USD Million in 2024, with projections indicating growth. **Q: What is the valuation of the Immunology application segment in the Pemphigus Market?** A: The Immunology application segment had a valuation of 144.0 USD Million in 2024, with future growth anticipated. **Q: How does the market for intravenous treatments compare to other routes of administration?** A: Intravenous treatments were valued at 231.78 USD Million in 2024, indicating a strong preference among treatment routes. **Q: What is the projected growth for the Geriatric demographic in the Pemphigus Market?** A: The Geriatric demographic was valued at 132.9 USD Million in 2024, with expectations for substantial growth by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pemphigus-market-6486*